Johnson Robert W, Talaty Nari
Discovery Chemistry and Technology, AbbVie Inc., 1 North Waukegan Road, North Chicago, Illinois 60064, United States.
ACS Med Chem Lett. 2019 Jan 11;10(2):161-167. doi: 10.1021/acsmedchemlett.8b00480. eCollection 2019 Feb 14.
Understanding the tissue distribution of therapeutic molecules is often critical for assessing their efficacy and toxicity. Unfortunately, standard methods for monitoring localized drug distribution are resource-intensive and are typically performed late in the discovery process. As a result, early development efforts often progress without detailed information on the effect that changes in structure and/or formulation have on drug localization. Recent innovations in mass spectrometry (MS) provide new options for mapping the spatial distribution of drug in tissue and allow parallel detection of endogenous species. These advances are improving access to drug distribution data early in discovery and provide insight into local biochemical changes that are directly related to drug activity. The literature on these topics is voluminous, and the technology is advancing rapidly, offering a bewildering array of options for researchers who are new to the field. To guide medicinal chemists who wish to apply these methods in their research, this technology perspective provides our views on practical applications that are currently enabled by various MS imaging (MSI) approaches, along with recommendations for how best to implement these methods in pharmaceutical R&D.
了解治疗性分子的组织分布对于评估其疗效和毒性通常至关重要。不幸的是,监测局部药物分布的标准方法资源消耗大,且通常在发现过程后期进行。因此,早期开发工作往往在缺乏关于结构和/或制剂变化对药物定位影响的详细信息的情况下推进。质谱(MS)领域的最新创新为绘制药物在组织中的空间分布提供了新选择,并允许对内源性物质进行并行检测。这些进展正在改善在发现早期获取药物分布数据的情况,并深入了解与药物活性直接相关的局部生化变化。关于这些主题的文献浩如烟海,技术也在迅速发展,为该领域的新手研究人员提供了令人眼花缭乱的各种选择。为了指导希望在研究中应用这些方法的药物化学家,本技术展望阐述了我们对当前各种质谱成像(MSI)方法所支持的实际应用的看法,以及关于如何在药物研发中最佳实施这些方法的建议。